9999999997-11-011390.txt : 20110608
9999999997-11-011390.hdr.sgml : 20110607
20110608154704
ACCESSION NUMBER: 9999999997-11-011390
CONFORMED SUBMISSION TYPE: CT ORDER
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20110608
DATE AS OF CHANGE: 20110608
20110608
20110608
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: PHARMACEUTICAL PRODUCT DEVELOPMENT INC
CENTRAL INDEX KEY: 0001003124
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 561640186
STATE OF INCORPORATION: NC
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: CT ORDER
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-27570
FILM NUMBER: 11900945
BUSINESS ADDRESS:
STREET 1: 929 NORTH FRONT STREET
CITY: WILMINGTON
STATE: NC
ZIP: 28401
BUSINESS PHONE: 9102510081
MAIL ADDRESS:
STREET 1: 929 NORTH FRONT STREET
CITY: WILMINGTON
STATE: NC
ZIP: 28401
CT ORDER
1
filename1.pdf
begin 644 filename1.pdf
M)5!$1BTQ+C4-)>+CS],-"C$P(#`@;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S
M=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@("`@#0HR
M,B`P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22`X-"],(#8X+TQE;F=T
M:"`V,B]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G``(.7P94P`C$+`P<#%LP(#`@-C$R(#7!E+T]B:E-T;3X^F<6@P&6_YS!L\H;C<$$!$N&[6LR`7[%)4M?M_HP
MDU5;I]O>8;/4I8&X+]B-VG[3V7ICT"?G[%8[J2=%R,:Y6C?@^=;A:%3MYKT@
MC*'G\0COQSFU1`NKCE61Y:]?TJS0#4SU'WBH"E5^M=I4%9I9!06;GR63U$J)
MJ;59;MBTJ@N5V]23<^.CF>]&Y=ER6*YS#9PE1A>/$+/3*;)JY##B4OH(E:U$A:I:1!#-#FE^`5+7[WXMGEA/>X?X,9HQ
M(8LYZ]4B[RJ]0QY1_"O``*6FB@D-"F5N9'-TA%9;;Z,X%'[/KSC2OIA5\6`'0IBW3"Z=5-MT-F&DE=K5BH"3L"*0X3*=
M_OL]OD!(>EFJ@C'VY^]\YY9/MQL&^VKP)1Q\"D,.#,+=@'%P\`\?@0.^,Z;!
M",+CP($]_H>QO#T/"%CAOSBT&64>A#,S$?YN!@CG&CB7.DRM&\EU-G4<%D@<
M,W@>/)+OJV4XMVR7!F0&&\OVJ$]"BS(R"?7LW$R"]7=X-[!'U/>]\]D2TQD9
M3#F0F)OY]/MZ&2XM7.TB`$Q6,\!#AG1$_II^G:QNS0M,'^[OEYO-\F&EX<>4
ML2MPUH(S9?Q=DPL8WP!W<*4TE].1UR/4UTE]MQFGCGL%VJK@&!4>UK/Y&FXM
M&PF0]605+E>W2&ZU4*P0P771+^UN;G9[7.]>SN:X8_('A.OY)+S'%R,6NR)G
M-FO=Y8GAUSFT:J%.\8J6P/*V>5QRC=VSSG?
M#E%YC&+1U&D<61YZ(8-O99$T<0TS\5-DQXA@7T9Y#<4.XB+?I0DR3=&*NA11?91J,.0_.G/MU&`F
M)'`#[(H2TASO,FDY,9(HKFD-XE><-0F:L2L+_0GJ0\M:PW^4M8]D_NN0;M.Z
M@KI`PHL"-?=E46&._2?L,$`2P)/NHQ<8ZMRF&ARKVG5\X527A'8OH[1/'?(E
MJC1:*4ZEJ-`X948%VQ#=C9HZP3R:1-65@CT@L+?%.1,3Y'
M!FH2U7C#3VEU=FG`WG.IB4:EN\1B1O$?392ENU14$%673HV+XU'H6H#ZL;-3
M_8ZOKT'+6*Y'K^[2/,K52^??H?*O1[I8Q##L^5,A7S#V6G<.-?BB%"(I='S+
MP%NV%@P-YB1&33SX3C=T2L'S^!/9/EE/Q-7<`^IX7J^B=O@J>\B3=:/XS-*?
M:27A\(AI(9T_IMP]&]TYR32'\E24^OR%,EK``054)8;[E%^G5I>TCDG:1-3"
MF)'F&$1Y4D)B$I(>$ZS#.U4,S5L!6:-Y6)F9B*J<)(1D:AO4@=M/)8'UWO?!Y*>
M%DS5%/E:IT><$V5:)%"=1"Q#._ELNK.&>[>;O,IVU_3V_[U,R<$20SG*9*[Z
M4!;-_@"34YEFP%Q5;4:]IN%>T3@7EN[9NY0D5]WF2I$SP,+H,<4DQO(78)60
MT7TC*]-5N&NI\0<@>ZO'^%J#:?$JX&]0^[)J9#^0#E,**Y2/&&+<9V(?J3;5
MU(>B3.N7SZWZ;SCD@P&7S1@W/!J5[BSNN_A[@0@YD-4RMY06YI'*:1^G=_)]
M>%Y6J@'BJF5K^>#GU4*MQL%>?^^V96HA'9.N?;1,-I;J^)R6?J:B]+R2K1Y./A/@`$`#WKV(@T*96YDG)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS
M.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835`@0V]R92`T
M+C(N,2UC,#0S(#4R+C,W,C&UL;G,Z6YT87@M;G,C(CX*("`@("`@/')D9CI$97-C
M&UL;G,Z9&,](FAT
M='`Z+R]P=7)L+F]R9R]D8R]E;&5M96YT&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O
M(CX*("`@("`@("`@/'AM<#I#&UP.D-R96%T
M;W)4;V]L/E!38W)I<'0U+F1L;"!697)S:6]N(#4N,BXR/"]X;7`Z0W)E871O
M&UP34TZ26YS=&%N8V5)
M1#YU=6ED.C-D-F,T93,T+3`W,60M-#9D8BTX-SEB+3EF.69D8C%D9#!F-CPO
M>&UP34TZ26YS=&%N8V5)1#X*("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@
M(#POJ'5!:DZ@?(RQ"L(P%`!_Y6TF
M@VD:4K52"L6N!5&Q2Y?:1!H(??+RQ-^W@[/;#7=7@H:JRIHWSTCB@LDO/(\Q
M=C([D1\YX-*.[$5[-#K/]4X?\L+:PFZUW6B]^5EK>KY.%%Y<*!W>[6R)UG77P$&`(U=058-"F5N9'-TF4@,3`O
M5'EP92]84F5F+U=;,2`R(#%=/CYS=')E86T-"FC>8F(``B9&KG<,3`R,;4""
M+Q[$Z@41G$")IS.`+`8&1B#!]!](,#(`!!@`?*(%&PT*96YD